GEnetics
Revelatory evaluations to advance awareness and individualize care
Backed by clinical data and developed by an experienced team of geneticists, genetic counselors, laboratory scientists, and bioinformaticians, our genetic testing is designed to deliver individualized insights that advance understanding of a patient’s inherited illness. Our full menu of genetic testing includes whole exome sequencing, fertility and prenatal testing, and disease-specific evaluations. Because test results can be complex, our genetic disease experts are available to answer questions about findings or the need for additional testing.
Highlights
Learn more about Mayo Clinic Laboratories’ new genome-wide methylation array from the Mayo Clinic neuro-oncology testing experts who worked alongside the National Institutes of Health to develop the innovative, first-in-class assay.
Inherited cardiovascular disorders are genetically diverse conditions that may affect cardiac structure or function and may be isolated or syndromic.
Viral and pharmacogenomic testing help clinicians detect infection early, tailor immunosuppression, and improve long-term outcomes for organ transplant recipients.
The rapidly evolving field of pharmacogenomics, the DPYD gene and its significance in oncology.
Cherisse Marcou, Ph.D., and Kristen Rasmussen, M.S., CGC, explain how Mayo Clinic Laboratories' WESPR whole exome sequencing reflex test provides cost-effective diagnosis of complex genetic conditions. Using samples and data from previous targeted gene panels, WESPR's wider net can identify undetected genetic variants.
PACE/State of FL - The critical role of pharmacogenomics and therapeutic drug monitoring (TDM) in managing immunosuppressive therapy for solid organ transplant recipients.
For many, the path to a correct diagnosis can be long and filled with uncertainty. This story highlights the resilience and determination of one patient who navigated a complex medical journey to find answers and hope at Mayo Clinic. The patient asked to remain anonymous for personal privacy reasons.
PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.
Justin Fugelsang and Zach Pedowitz have never met. Yet both young men were diagnosed with a rare form of Charcot-Marie-Tooth disease, called sorbitol dehydrogenase (SORD) deficiency, and both found clarity through Mayo Clinic Laboratories' innovative SORD testing. Their journeys inspire resilience, as Justin has channeled his emotions into guitar playing, and Zach has embraced educational leadership.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by genetic counselors Carrie Lahner, M.S., CGC, and April Studinski Jones, M.S., CGC, to discuss how family medical history can inform genetic testing strategies.
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.